These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37315221)

  • 1. Synthetic Biology Facilitates Semisynthetic Development of Type V Glycopeptide Antibiotics Targeting Vancomycin-Resistant
    Koteva K; Xu M; Wang W; Fiebig-Comyn AA; Cook MA; Coombes BK; Wright GD
    J Med Chem; 2023 Jul; 66(13):9006-9022. PubMed ID: 37315221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond vancomycin: recent advances in the modification, reengineering, production and discovery of improved glycopeptide antibiotics to tackle multidrug-resistant bacteria.
    Hansen MH; Stegmann E; Cryle MJ
    Curr Opin Biotechnol; 2022 Oct; 77():102767. PubMed ID: 35933924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redesign of glycopeptide antibiotics: back to the future.
    James RC; Pierce JG; Okano A; Xie J; Boger DL
    ACS Chem Biol; 2012 May; 7(5):797-804. PubMed ID: 22330049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
    Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pursuit of next-generation glycopeptides: a journey with vancomycin.
    Acharya Y; Dhanda G; Sarkar P; Haldar J
    Chem Commun (Camb); 2022 Feb; 58(12):1881-1897. PubMed ID: 35043130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
    Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
    Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin.
    Wu ZC; Boger DL
    Acc Chem Res; 2020 Nov; 53(11):2587-2599. PubMed ID: 33138354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPAHex-A synthetic biology platform for Type IV-V glycopeptide antibiotic production and discovery.
    Xu M; Wang W; Waglechner N; Culp EJ; Guitor AK; Wright GD
    Nat Commun; 2020 Oct; 11(1):5232. PubMed ID: 33067466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Vancomycin-Resistant Enterococcus Strains in the West Balkans: A First Report.
    Jakovac S; Bojić EF; Ibrišimović MA; Tutiš B; Ostojić M; Hukić M
    Microb Drug Resist; 2017 Jan; 23(1):122-126. PubMed ID: 27351410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B.
    Yoshida O; Yasukata T; Sumino Y; Munekage T; Narukawa Y; Nishitani Y
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3027-31. PubMed ID: 12372494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in Glycopeptide Antibiotics.
    Blaskovich MAT; Hansford KA; Butler MS; Jia Z; Mark AE; Cooper MA
    ACS Infect Dis; 2018 May; 4(5):715-735. PubMed ID: 29363950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.
    Yoganathan S; Miller SJ
    J Med Chem; 2015 Mar; 58(5):2367-77. PubMed ID: 25671771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria.
    Miura K; Yamashiro H; Uotani K; Kojima S; Yutsudo T; Lu J; Yoshida O; Yamano Y; Maki H; Arimoto H
    Antimicrob Agents Chemother; 2010 Feb; 54(2):960-2. PubMed ID: 19933802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
    Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of clinical enterococci isolates, focusing on the vancomycin-resistant enterococci in a tertiary hospital in China: based on the data from 2013 to 2018.
    Zhou W; Zhou H; Sun Y; Gao S; Zhang Y; Cao X; Zhang Z; Shen H; Zhang C
    BMC Infect Dis; 2020 May; 20(1):356. PubMed ID: 32517758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.